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to IFN-a. J Med Virol 2006; 78:74–82.Utilizing nucleic acid amplification to identify acute HIV infectionTruong et al. [1] noted an 8% increase in acute infection
detection when nucleic acid amplification testing is
incorporated into standard HIV testing. Following a
high-risk cohort in South Africa, we have similarly
noted the benefits of nucleic acid amplification testing
for the identification of acute HIV infection before
seroconversion.
It is important to identify patients with acute HIV
infection as a potentially useful opportunity to implement
interventions that may reduce HIV transmission in the
light of data that suggest that the probability of trans-
mission may be increased by up to 10-fold during the
acute phase of infection [2–5]. The identification of acute
HIV infection is also important for research on HIV
diagnostics, vaccines, microbicides and the early initiation
of antiretroviral therapy [5].Current routine HIV antibody tests and clinical criteria
are not effective in distinguishing between acute and
established HIV infection. Frequent HIV testing of
high-risk individuals is one strategy to identify those
with recent HIV infection, but this is impractical and
costly [6]. Laboratory techniques such as the standar-
dized algorithm for recent HIV seroconversion [sensi-
tive/less sensitive ‘detuned’ enzyme-linked immuno-
sorbent assay (ELISA) or the BED assay] have been
utilized to identify recent HIV infections [7]. These tests
have questionable accuracy, however, and they only
indicate whether an individual seroconverted within the
past few hundred days, and cannot therefore distinguish
between recent and acute HIV infection. Strategies using
the p24 antigen ELISA have been used to identify acute
HIV infection before seroconversion in some settings,
e.g. blood banks.orized reproduction of this article is prohibited.
Co
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acid amplification (polymerase chain reaction; PCR) has
recently been proposed to identify acute HIV infection in
those testing negative with standard HIVantibody testing,
thereby detecting individuals with acute infection who
are viraemic but antibody negative [8,9]. This approach
has the advantage of an earlier diagnosis of acute HIV
infection than with the p24 antigen assay.
To assess the potential utility of this PCR method in a
resource-constrained setting, we followed a cohort of 245
HIV-negative high-risk sex workers established as part of
the CAPRISA 002 Acute Infection Study, which is a
prospective observational cohort study being conducted
at the Centre for the AIDS Programme of Research in
South Africa (CAPRISA) in Durban, South Africa.
Acute HIV infection was determined according to the
testing algorithm in Fig. 1, i.e. a positive RNA PCR at a
study visit that follows a previous monthly visit at which
the individual was found to have a negative HIV-RNA
PCR. HIV-RNA PCR was performed using the Cobas
AmpliScreen Multiprep HIV-1 test version 1.5 and the
Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Test,
version 1.5 (Roche Diagnostics, Branchburg, New Jersey,
USA). The first step in the testing algorithm is testing
with two rapid HIV tests: the Determine HIV-1 test
(Abbott Diagnostics, Johannesburg, South Africa) and
the Capillus HIV-1/HIV-2 test (Trinity Biotech, USA).
Patients with at least one negative rapid HIV test are then
tested by RNA PCR. RNA-PCR-positive samples are
then tested by an ELISA using Enzynost anti-HIV-1/2
plus (Dade Behring, Deerfield, Illinois, USA) to confirm
the absence of anti-HIV antibodies.
Of the 23 acute HIV infections identified using this
algorithm, 14 were identified through two concordant
positive results on rapid HIV tests, three were negative on
both the HIV rapid tests but were found to be ELISA
positive, and six were rapid HIV test and ELISA negative.pyright © Lippincott Williams & Wilkins. Unauthor
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Fig. 1. HIV testing algorithm. ELISA, Enzyme-linked immu-
nosorbent assay; PCR, polymerase chain reaction.All 23 were RNA-PCR positive and were confirmed at
later timepoints to be HIV seropositive by ELISA. The
RNA-PCR cutoff used for positivity was greater than
1000 copies, and no false RNA positives were identified.
There were 14 instances of discordant rapid HIV test
results, and all were found to be HIV-RNA-PCR
negative.
As the pre-antibody window period during which there
is viral replication and detectable virus in the blood is
short, monthly testing with two rapid HIV tests was able
to detect 60.8% of patients (14/23) with acute HIV
infection. If ELISA testing is added to the testing strategy,
in addition to the rapid HIV tests (without PCR), then
the detection of acute HIV infection increases from 14 to
17 of the 23 (73.9%) cases as a result of the false-negative
rapid tests at low levels of anti-HIV antibodies. Incor-
porating RNA-PCR testing after two rapid HIV tests
into the HIV testing strategy in this cohort increased the
detection of acute HIV infections by 39.1%.
The incorporation of nucleic acid amplification testing
into standard HIV antibody testing, either by ELISA or
rapid HIV tests, is a potentially useful strategy for screen-
ing for acute HIV infection in populations at high risk of
HIV acquisition. RNA PCR improves the detection of
acute HIV infection substantially in high-risk cohorts,
and could potentially have wider public health applica-
tions in a generalized population level epidemic with high
HIV incidence rates, such as the HIV epidemic in South
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